Your treatment options,
explained
Understand the clinically-proven GLP-1 medications our physicians prescribe. Each works differently — find the right fit for your body and goals.
How GLP-1 Medications Work
All three medications share a common foundation — they mimic natural hormones to help your body manage weight.
Reduces appetite
Signals your brain's hunger centers to feel satisfied sooner and longer, naturally reducing calorie intake.
Slows digestion
Slows gastric emptying so food stays in your stomach longer, helping you feel full between meals.
Regulates blood sugar
Improves insulin response and stabilizes glucose levels, reducing cravings and energy crashes.
Ozempic
Semaglutide · Novo Nordisk
The proven GLP-1 that started it all
Originally developed for type 2 diabetes, Ozempic has demonstrated significant weight loss in clinical trials. As a GLP-1 receptor agonist, it mimics a natural hormone to reduce appetite and slow gastric emptying — helping patients lose 10-15% of their body weight.
Type
GLP-1 Agonist
Frequency
Once Weekly
Weight Loss
10–15%
Approval
Health Canada
Dose titration schedule
Your doctor adjusts your dose gradually for best results
Starting dose — your body adjusts
Therapeutic dose begins
Maintenance dose — maximum effect
Common side effects
Usually temporary and improve as your body adjusts
Dose titration schedule
5-step escalation to maximum therapeutic dose
Maintenance dose — maximum therapeutic effect
How is Wegovy different from Ozempic?
Same active ingredient (semaglutide), but Wegovy reaches a higher maximum dose — 2.4mg vs 1mg. It's also the first semaglutide specifically approved for chronic weight management, not just diabetes.
Wegovy
Semaglutide (higher dose) · Novo Nordisk
The first GLP-1 approved specifically for weight management
Wegovy is the same molecule as Ozempic — semaglutide — but at a higher dose and with specific approval for chronic weight management. Clinical trials (STEP program) showed patients losing an average of 15% of their body weight over 68 weeks.
Type
GLP-1 Agonist
Max Dose
2.4 mg/week
Weight Loss
~15%
Approved For
Weight Loss
Mounjaro
Tirzepatide · Eli Lilly
Dual-action. Next generation. Most potent results.
Mounjaro is the first dual GIP/GLP-1 receptor agonist — it targets two hormones instead of one. In the SURMOUNT-1 trial, participants achieved up to 22.5% body weight loss over 72 weeks, making it the most potent option available.
Dual-action mechanism
Together, these two pathways produce significantly greater weight loss than GLP-1 alone.
Type
Dual GIP/GLP-1
Weight Loss
Up to 22.5%
Frequency
Once Weekly
Clinical Trial
SURMOUNT-1
Dose titration schedule
6-step escalation — the most gradual and customizable
Maintenance dose — maximum therapeutic effect
Common side effects
Similar to other GLP-1s — typically mild and temporary
Compare at a Glance
All three medications are clinically proven, Health Canada approved, and prescribed by our licensed physicians.
| Feature | Ozempic | Wegovy POPULAR | Mounjaro |
|---|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 | GLP-1 | GIP + GLP-1 |
| Max Dose | 1 mg | 2.4 mg | 15 mg |
| Weight Loss | 10–15% | ~15% | Up to 22.5% |
| Injection | Weekly | Weekly | Weekly |
| Dose Steps | 3 | 5 | 6 |
| Originally For | Type 2 Diabetes | Weight Loss | Type 2 Diabetes |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly |
Ozempic
Semaglutide · Novo Nordisk
Wegovy
Semaglutide · Novo Nordisk
Mounjaro
Tirzepatide · Eli Lilly
Your doctor will recommend the best medication based on your health profile, medical history, and treatment goals. All data from peer-reviewed clinical trials.
Ready to find your
treatment?
Take our free 5-minute health assessment. A licensed physician will review your profile and recommend the right medication for you.
Free consultation · No commitment · Cancel anytime